scorecardresearch
Follow Us:
Tuesday, November 24, 2020

Some districts trying to control the testing for Covid-19: Thyrocare MD

Thyrocare is among the top five diagnostic centres in the country, and has been collecting samples in several high Covid-19 caseload states including Maharashtra, Karnataka, Tamil Nadu, Bihar, West Bengal, Jammu and Kashmir, Jharkhand, Uttar Pradesh, Delhi, and Uttarakhand.

Written by Prabha Raghavan | New Delhi | Updated: October 29, 2020 7:45:44 am
People get tested for Covid 19 at a weekly market in Patparganj, New Delhi on Wednesday. (Express Photograph by Tashi Tobgyal)

The managing director of one of India’s top private diagnostic labs has said that government authorities in some districts have been trying to “control” the process of testing for the novel coronavirus in order to show a “better scorecard”.

“Even though testing has been opened up, the government is still controlling private centre testing at district levels. It is happening more today than before. We have been told not to pick up samples in many districts in different states, claiming that we are reporting false positives,” A Velumani, founder and managing director of Thyrocare Technologies, told The Indian Express.

Thyrocare is among the top five diagnostic centres in the country, and has been collecting samples in several high Covid-19 caseload states including Maharashtra, Karnataka, Tamil Nadu, Bihar, West Bengal, Jammu and Kashmir, Jharkhand, Uttar Pradesh, Delhi, and Uttarakhand.

Also Read | Dr Reddy’s looks to complete late-stage trials of Sputnik V by mid-May next year

“Around 2,000 of our samples are reduced every day across at least 100 districts because of this, and one of the motivations is obviously they don’t really want to show a higher positivity scorecard. They want to show a better scorecard,” Velumani said.

Thyrocare has been facing this problem in 30 per cent of the districts it collects samples from, Velumani said. He declined to name the districts where lab staff were allegedly being told verbally to limit testing.

Ameera Shah, managing director of diagnostic chain Metropolis Healthcare, underlined the crucial importance of testing at this stage of the pandemic in India. “The more we increase testing and the more that we take care of those who are Covid-19 positive and do rigorous contact tracing, the better our chances of avoiding a possible next spike that is expected to come in the October to December quarter,” Shah said.

Ameera Shah, managing director of diagnostic chain Metropolis Healthcare, underlined the crucial importance of testing at this stage of the pandemic in India. (Express Photograph by Tashi Tobgyal)

A senior executive of another large diagnostic firm confirmed they too were facing issues similar to the ones flagged by Velumani.

This executive, who declined to be identified, said certain parts of Maharashtra and Gujarat had been engaging in such practices in the recent past.

Also Read | Covaxin: Bharat Biotech aims to improve clinical results by at least 60%, above regulator cut-off mark

“We continue to see this happening. We’re not seeing this evenly spread everywhere, but in certain places. It’s random and arbitrary, and happening across different districts across the country,” the executive told The Indian Express. As a result, the firm has been unable to ramp up testing to its full capacity, the executive said.

“Basically, states have their own pressures for not wanting to show positive cases. Because the pressure is trickled down, at the district level, we are finding that people are telling us to do a maximum total number of tests per day,” the executive added.

A top executive of another major diagnostic firm, however, told The Indian Express that issues such as the one flagged by Velumani had been more common “a few months ago”.

Thyrocare has been facing this problem in 30 per cent of the districts it collects samples from, Velumani said. (Express Photograph by Tashi Tobgyal)

The executive of the first firm said some district authorities had also instructed them to run the results by the authorities before releasing the final reports to the Indian Council of Medical Research (ICMR).

Covid-19 vaccines status check: Moderna, Pfizer aim to deliver shot by December

“They have said that if they tell us to not release it (the reports), then we shouldn’t release it… This is possibly affecting the number of tests being done and, possibly, the number of positives coming out,” this executive said.

Asked for a comment, ICMR’s media coordinator told The Indian Express: “All the issues highlighted are within the purview of the respective state governments. ICMR is a research body, which has played a pivotal role in guiding states on testing protocols and modalities… ICMR does not have any regulatory authority. All states are free to decide on the levels of engagement with the private and public sector.”

The Health Ministry has stated that India is among the “topmost” countries in testing. Since October 1, the country has tested between 8.5 lakh and 14.7 lakh samples every day. Cumulative tests since the pandemic began crossed 10.5 crore on Wednesday.

📣 The Indian Express is now on Telegram. Click here to join our channel (@indianexpress) and stay updated with the latest headlines

For all the latest India News, download Indian Express App.

0 Comment(s) *
* The moderation of comments is automated and not cleared manually by indianexpress.com.
Advertisement
Advertisement
Advertisement
Advertisement